Cocrystal Pharma (COCP) Net Equity Issued and Repurchased (2012 - 2021)

Cocrystal Pharma has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $2.1 million in Q1 2021.

• Quarterly Net Equity Issued and Repurchased fell 87.52% year-over-year to $2.1 million in Q1 2021, while the trailing twelve-month figure through Sep 2023 was $2.1 million (changed N/A YoY) and the FY2025 annual result came in at $154000.0, changed N/A from the prior year.
• Net Equity Issued and Repurchased slipped to $2.1 million in Q1 2021 per COCP's latest filing, from $3.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $16.6 million in Q1 2020 and troughed at -$744000.0 in Q2 2018.
• A 4-year average of $4.7 million and a median of $3.2 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2020 and 2021: Net Equity Issued and Repurchased jumped 322.76% in 2020, then plunged 87.52% in 2021.
• Over 4 years, Net Equity Issued and Repurchased stood at -$744000.0 in 2018, then surged by 464.25% to $2.7 million in 2019, then surged by 33.65% to $3.6 million in 2020, then tumbled by 42.79% to $2.1 million in 2021.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $2.1 million, $3.6 million, and $16.6 million for Q1 2021, Q4 2020, and Q1 2020 respectively.